Replies to post #7375 on Avid Bioservices Inc (CDMO)

[DewDiligence]

>In the mean time, I note the rumor (not yet confirmed by me) that Company hopes to present HCV repeat dose data at AASLD Annual Meeting in Boston Oct 27-31.<

I wouldn’t call it a rumor. On the CC they said the data would be presented at a major conference in the fall; as mskatie mentioned, this clearly means AASLD.

[technicalwin]

Just in time for the SHM. As I said. management will release data when it fits into their plans. TW

[mskatiescarletohara]

BOT, it's a coincidence, the company could have announced enrollment in July and it would still meet the late-breaking parameters. Godofsky has until Aug 9 to submit results from the 6mg dosing cohort. If there are good results from the repeat dose study, we'll know about it at this meeting.

Late Breaking Abstracts

Original late-breaking scientific research that was conducted and submitted after June 7, 2006 will be reviewed for presentation at The Liver Meeting®.

Abstracts should only be submitted as “late-breaking” abstracts if the research is either the result of a large clinical study, or translational research of high impact. Competitive late-breaking abstracts should report study results of high therapeutic relevance, diagnostic importance, or information impacting current patient management.

The late-breaking abstract submitter is open August 1-9, 2006.